<DOC>
	<DOCNO>NCT00726232</DOCNO>
	<brief_summary>To evaluate safety efficacy profile different treatment regimen Ruxolitinib ( INCB018424 ) administer two group patient ; polycythemia vera ( PV ) essential thrombocythemia ( ET ) . Patients group refractory hydroxyurea hydroxyurea contraindicate .</brief_summary>
	<brief_title>Study Determine Safety Efficacy Ruxolitinib ( INCB018424 ) Patients With Polycythemia Vera Essential Thrombocythemia</brief_title>
	<detailed_description>The study consist 2-stage design , include dose-ranging phase ( patient receive treatment randomize dose ) expansion phase ( adjustment dose/regimen achieve optimal balance efficacy safety ) . During dose-ranging phase , patient disease group ( PV ET ) randomly assign 1:1:1 ratio independent receive 1 3 treatment regimen Ruxolitinib , 10 mg twice daily ( bid ) , 25 mg bid , 50 mg daily ( qd ) . After patient complete 2 cycle treatment Ruxolitinib randomize dose , Investigators permit adjust dose/regimen individual basis use discretion order achieve optimal balance efficacy safety . During expansion phase ( ie , optimization dose ) , additional patient PV ET enrol receive Ruxolitinib dose select upon review data dose-ranging phase . Treatment continue patient met withdrawal criterion , intolerable toxicity , progression disease , withdraw consent .</detailed_description>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Confirmed diagnosis polycythemia vera essential thrombocythemia determine treat physician Disease refractory hydroxyurea treatment hydroxyurea contraindicate refused treatment hydroxyurea due side effect . Patient meet baseline clinical lab parameter Treatment interferon alpha anagrelide within 7 day hydroxyurea within 1 day start INCB018424 . Patients diagnose another malignancy unless malignancy cervical intraepithelial neoplasia basal squamous cell skin cancer patient disease free &gt; 3 year Patients receive therapy intermediate high dose steroid great equivalent 10 mg prednisone per day Clinically significant cardiac disease ( New York Heart Association ( NYHA ) Class III IV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>